Literature DB >> 21276572

Combination of copeptin and high-sensitivity cardiac troponin T assay in unstable angina and non-ST-segment elevation myocardial infarction: a pilot study.

Christophe Meune1, Stéphane Zuily, Karim Wahbi, Yann-Erick Claessens, Simon Weber, Camille Chenevier-Gobeaux.   

Abstract

BACKGROUND: High-sensitivity cardiac troponin assays have improved the detection of acute coronary syndrome. AIM: To examine the possible incremental value of copeptin in the detection of acute coronary syndrome.
METHODS: We designed a prospective cohort study to compare the performance of high-sensitivity cardiac troponin T (hs-cTnT) measured at admission in combination with copeptin, and the performance of hs-cTnT alone, measured at admission, 3 hours and 6 hours, in patients with suspected acute coronary syndrome of < 6 hours' duration after onset of symptoms (exclusion of patients with ST-segment elevation myocardial infarction).
RESULTS: Fifty-eight consecutive patients fulfilled our criteria and were included. After detailed investigations, the final adjudicated diagnosis was acute coronary syndrome in 30 patients (including acute myocardial infarction in 13 and unstable angina in 17) and non-acute coronary syndrome in 28 patients. Measured on admission, hs-cTnT concentration was > 14 ng/mL (99 th percentile) in 22 patients with acute coronary syndrome; repetition of the measurement at 3 hours and 6 hours identified three and four additional patients, respectively. The combination of copeptin with hs-cTnT determined on admission identified 26 patients with acute coronary syndrome, with a negative predicted value of 82.6%. The area under the receiver operating characteristic curve was 0.90 for hs-cTnT measured on admission, and 0.94 if repeated at 3 hours and 6 hours or combined with copeptin measurement at admission (non-significant difference).
CONCLUSIONS: This prospective study demonstrated that a dual marker strategy that combines hs-cTnT with copeptin increased slightly the detection of acute coronary syndrome at admission.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21276572     DOI: 10.1016/j.acvd.2010.11.002

Source DB:  PubMed          Journal:  Arch Cardiovasc Dis        ISSN: 1875-2128            Impact factor:   2.340


  13 in total

Review 1.  Effectiveness of practices for improving the diagnostic accuracy of Non ST Elevation Myocardial Infarction in the Emergency Department: A Laboratory Medicine Best Practices™ systematic review.

Authors:  Christopher Layfield; John Rose; Aaron Alford; Susan R Snyder; Fred S Apple; Farah M Chowdhury; Michael C Kontos; L Kristin Newby; Alan B Storrow; Milenko Tanasijevic; Elizabeth Leibach; Edward B Liebow; Robert H Christenson
Journal:  Clin Biochem       Date:  2015-02-07       Impact factor: 3.281

Review 2.  The Emerging Role of Copeptin.

Authors:  R Jalleh; D J Torpy
Journal:  Clin Biochem Rev       Date:  2021-02

Review 3.  Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases.

Authors:  Danni Mu; Jin Cheng; Ling Qiu; Xinqi Cheng
Journal:  Front Cardiovasc Med       Date:  2022-07-04

4.  Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor.

Authors:  María-Consuelo Pintado; Lara Maceda; María Trascasa; Ignacio Arribas; Raúl De Pablo
Journal:  Egypt Heart J       Date:  2022-04-28

5.  Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction.

Authors:  Youlan L Gu; Adriaan A Voors; Felix Zijlstra; Hans L Hillege; Joachim Struck; Serge Masson; Tarcisio Vago; Stefan D Anker; Ad F M van den Heuvel; Dirk J van Veldhuisen; Bart J G L de Smet
Journal:  Clin Res Cardiol       Date:  2011-07-16       Impact factor: 5.460

Review 6.  Copeptin testing in acute myocardial infarction: ready for routine use?

Authors:  Sebastian Johannes Reinstadler; Gert Klug; Hans-Josef Feistritzer; Bernhard Metzler; Johannes Mair
Journal:  Dis Markers       Date:  2015-04-16       Impact factor: 3.434

7.  No Added Value of Novel Biomarkers in the Diagnostic Assessment of Patients Suspected of Acute Coronary Syndrome.

Authors:  Judith M Poldervaart; Emma Röttger; Marieke S Dekker; Nicolaas P A Zuithoff; Peter W H M Verheggen; Evelyn A de Vrey; Thierry X Wildbergh; Arnoud W J van 't Hof; Arend Mosterd; Arno W Hoes
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

8.  The combination of high sensitivity troponin T and copeptin facilitates early rule-out of ACS: a prospective observational study.

Authors:  Johan Thelin; Catharina Borna; David Erlinge; Bertil Öhlin
Journal:  BMC Cardiovasc Disord       Date:  2013-06-18       Impact factor: 2.298

Review 9.  Copeptin and its potential role in diagnosis and prognosis of various diseases.

Authors:  Lidija Dobsa; Kido Cullen Edozien
Journal:  Biochem Med (Zagreb)       Date:  2013       Impact factor: 2.313

10.  Diagnostic accuracy of copeptin sensitivity and specificity in patients with suspected non-ST-elevation myocardial infarction with troponin I below the 99th centile at presentation.

Authors:  Jonathan Duchenne; Stéphanie Mestres; Nicolas Dublanchet; Nicolas Combaret; Geoffroy Marceau; Laurent Caumon; Laurent Dutoit; Sylvie Ughetto; Pascal Motreff; Vincent Sapin; Jeannot Schmidt
Journal:  BMJ Open       Date:  2014-03-24       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.